Renaissance Technologies’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Renaissance Technologies’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,441	Closed	-$90K	–	4422
2023 Q1	$90K	Sell	7,441 -6,798	-48%	-$70.6K	﹤0.01%	3521
2022 Q4	$65K	Buy	14,239 +2,215	+18%	+$12.6K	﹤0.01%	3742
2022 Q3	$79K	Sell	12,024 -5,535	-32%	-$50.5K	﹤0.01%	3659
2022 Q2	$189K	Sell	17,559 -3,641	-17%	-$49K	﹤0.01%	3672
2022 Q1	$405K	Buy	21,200 +12,053	+132%	+$269K	﹤0.01%	3317
2021 Q4	$328K	Buy	9,147 +6,893	+306%	+$392K	﹤0.01%	3300
2021 Q3	$166K	Buy	+2,254	New	+$173K	﹤0.01%	3244

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies's SGTX Position: Q2 2023 in Review

Renaissance Technologies sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 7,441 shares — an estimated $90K sold.

Renaissance Technologies first reported a position in SGTX in Q3 2021 and held it in 7 quarters. The position peaked at $405K in Q1 2022. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Renaissance Technologies reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Renaissance Technologies sold 7,441 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $90K.
Renaissance Technologies first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Renaissance Technologies's Sigilon Therapeutics, Inc. Common Stock position peaked at $405K in Q1 2022.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.